• Spark Therapeutics to Invest $575M in New State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus

  December 17, 2021

  Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced plans to invest an initial $575M in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood. Through a 99-year ground lease of Drexel University’s F Lot, the new center will be located at the intersection of 30th and Chestnut Streets and will create opportunities for collaboration with Drexel University and Philadelphia’s booming life sciences community. Terms of the ground lease, including financial terms, were not disclosed.

  Read More